<SEC-DOCUMENT>0001193125-22-086848.txt : 20220328
<SEC-HEADER>0001193125-22-086848.hdr.sgml : 20220328
<ACCEPTANCE-DATETIME>20220328171702
ACCESSION NUMBER:		0001193125-22-086848
CONFORMED SUBMISSION TYPE:	DEFR14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220328
DATE AS OF CHANGE:		20220328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BAXTER INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000010456
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				360781620
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFR14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-04448
		FILM NUMBER:		22776390

	BUSINESS ADDRESS:	
		STREET 1:		ONE BAXTER PKWY
		STREET 2:		DF2-1W
		CITY:			DEERFIELD
		STATE:			IL
		ZIP:			60015
		BUSINESS PHONE:		8479482000

	MAIL ADDRESS:	
		STREET 1:		ONE BAXTER PARKWAY
		STREET 2:		DF2-1W
		CITY:			DEERFIELD
		STATE:			IL
		ZIP:			60015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BAXTER TRAVENOL LABORATORIES INC
		DATE OF NAME CHANGE:	19880522

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BAXTER LABORATORIES INC
		DATE OF NAME CHANGE:	19760608
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFR14A
<SEQUENCE>1
<FILENAME>d320042ddefr14a.htm
<DESCRIPTION>DEFR14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFR14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.1) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9746;&nbsp;&nbsp;Filed by the
Registrant&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the Registrant </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CHECK THE APPROPRIATE BOX: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, For Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Under Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320042g0328150059642.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Baxter International Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials: </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT TO PROXY STATEMENT DATED MARCH&nbsp;21, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE 2022 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON MAY&nbsp;3, 2022 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
Amendment No.1 to the Proxy Statement, dated March&nbsp;28, 2022 (this &#147;Amendment&#148;), amends the definitive proxy statement filed by Baxter International, Inc. (the &#147;Company&#148;) with the U.S. Securities and Exchange Commission
(&#147;SEC&#148;) on March&nbsp;21, 2022 (the &#147;2022 Proxy Statement&#148;) and made available to the Company&#146;s stockholders in connection with the solicitation of proxies by the Company&#146;s Board of Directors (the &#147;Board&#148;) for
use at the 2022 Annual Meeting of Stockholders, scheduled to be held virtually on Tuesday, May&nbsp;3, 2022 at 9:00 AM Central Time (the &#147;Annual Meeting&#148;). This Amendment is being filed with the SEC and made available to stockholders on or
about March&nbsp;28, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment updates the disclosure in the 2022 Proxy Statement on the voting requirements for and the effect of abstentions
and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> on &#147;Proposal 4: Approval of Certificate of Incorporation Amendment to Permit Stockholder Action by Written Consent&#148; (&#147;Proposal 4&#148;) and &#147;Proposal 5: Approval of
Certificate of Incorporation Amendment to Lower the Special Meeting Threshold&#148; (&#147;Proposal 5&#148;). Proposal 4 and Proposal 5 each require the affirmative vote of the holders of at least a majority of the outstanding shares of the
Company&#146;s common stock. Abstentions will have the effect of a vote against the approval of these Proposals. Nominees such as banks and brokers holding shares on behalf of beneficial owners who do not provide voting instructions may not vote the
related shares with respect to Proposal 4 or Proposal 5. These broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will also have the effect of a vote against approval of these Proposals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments to Proposal 4 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The vote required to approve
Proposal 4 as described on page 80 of the 2022 Proxy Statement under the heading &#147;Vote Required&#148; is hereby amended and restated in its entirety as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Approval of this Proposal 4 requires the affirmative vote of a majority of the outstanding shares of the company&#146;s Common Stock.
Abstentions will have the effect of a vote against the approval of this Proposal 4. Nominees such as banks and brokers holding shares on behalf of beneficial owners who do not provide voting instructions may not vote the related shares with respect
to this Proposal 4. These broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will also have the effect of a vote against approval of this Proposal 4. If this Proposal 4 is approved by the company&#146;s stockholders, the resulting Certificate
of Incorporation will be filed with the Secretary of State of the State of Delaware shortly after the Annual Meeting. If this Proposal 4 is not approved by the company&#146;s stockholders, this Proposal will not be implemented and stockholders will
not have the right to act by written consent.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The description of the vote required to approve Proposal 5 (which also requires an amendment to the
Company&#146;s Certificate of Incorporation) under the heading &#147;Vote Required&#148; on page 83 of the 2022 Proxy Statement is correct and does not need to be revised. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments to the Questions and Answers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the
answers to the following questions contained on pages 93 and 94 of the 2022 Proxy Statement are hereby revised in their entirety to read as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Q: How is it determined whether a matter has been approved? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A:</B> Assuming a quorum is present, the approval of the matters specified in the Notice of Annual Meeting of Stockholders will be
determined as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each director nominee under Proposal 1 receiving a majority of votes cast (number of shares voted &#147;for&#148;
a director must exceed 50% of the number of votes cast with respect to that director) will be elected as a director; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal 4 and Proposal 5 require the affirmative vote of a majority of the outstanding shares of common stock of
the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each other matter requires the affirmative vote of a majority of the shares of common stock, present virtually or
by proxy and entitled to vote at the Annual Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What are broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> and what effect do they have? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A:</B> Broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> occur when nominees, such as banks and brokers holding shares on behalf of beneficial owners, do not receive voting instructions from the beneficial holders. If that happens, the nominees may vote
those shares only on matters deemed &#147;routine&#148; by the NYSE, such as the ratification of the appointment of the company&#146;s independent registered public accounting firm. On <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT>
matters nominees cannot vote unless they receive voting instructions from beneficial owners, resulting in so called &#147;broker <FONT STYLE="white-space:nowrap">non-votes.&#148;</FONT> The items being considered at the Annual Meeting, except for
the ratification of the appointment of the company&#146;s independent registered public accounting firm, under &#147;Proposal 3&#151;Ratification of Independent Registered Public Accounting Firm,&#148; are considered
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will
have no impact on &#147;Proposal 1&#151;Election of Directors,&#148; &#147;Proposal 2&#151;Advisory Vote to Approve Named Executive Compensation,&#148; &#147;Proposal 6&#151;Special Shareholder Meeting Improvement&#148; or &#147;Proposal
7&#151;Independent Board Chairman.&#148; Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have the same effect as a vote against &#147;Proposal 4&#151;Approval of Certificate of Incorporation Amendment to Permit Stockholder Action by
Written Consent,&#148; and &#147;Proposal 5&#151;Approval of Certificate of Incorporation Amendment to Lower the Special Meeting Threshold.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What effect does an abstention have? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A:</B> Abstentions or directions to withhold authority will have no effect on the outcome of Proposal 1. Abstentions will have the same
effect as a vote against any of the other matters specified in the Notice of Annual Meeting of Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described in this Amendment, none
of the items or information presented in the 2022 Proxy Statement is affected by this Amendment. This Amendment does not provide all of the information that is important to your voting decisions at the Annual Meeting, and the 2022 Proxy Statement
contains other important additional information. <B>This Amendment should be read in conjunction with the 2022 Proxy Statement.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have already
returned your proxy or voting instruction card or provided voting instructions, you do not need to take any action unless you wish to change your vote. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g320042g0328150059642.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320042g0328150059642.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  @ +@# 2(  A$! Q$!_\0
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A3+/:4:.!=RL,$,>2#^)IXN:Y+(*,7S79LT445YQTG__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
